CRGX (Cargo Therapeutics) Pre-Tax Income : $-167.50 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Cargo Therapeutics's pretax income for the three months ended in Dec. 2024 was $-45.44 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-167.50 Mil. Cargo Therapeutics's pretax margin was %.

Cargo Therapeutics Pre-Tax Income Historical Data

The historical data trend for Cargo Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics Pre-Tax Income Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

-5.85

-40.95

-98.15

-167.50

Cargo Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial						-32.08	-35.81	-44.35	-41.91	-45.44

Competitive Comparison of Cargo Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Cargo Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cargo Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cargo Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cargo Therapeutics's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Cargo Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cargo Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-187.37	+	-0.195	+	0	+	20.063	+	0
	=	-167.50

Cargo Therapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-50.134	+	0.031	+	0	+	4.668	+	0
	=	-45.44

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-167.50 Mil.

Cargo Therapeutics (NAS:CRGX) Pre-Tax Income Explanation

Cargo Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-45.435	/	0
	=	%

Cargo Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cargo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.